Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
World J Surg Oncol. 2023 Feb 6;21(1):35. doi: 10.1186/s12957-023-02916-y.
Systematic evaluation of the effectiveness and safety of laparoscopic radical nephrectomy (LRN) for renal tumor (>7 cm).
The databases PubMed, Scopus, SinoMed, ScienceDirect, and Google Scholar were systematically searched for trials up to November 2022. The pooled results were evaluated by weighted mean difference (WMD), odds ratio (OR), and hazard ratio (HR).
This meta-analysis (18 trials) demonstrated that compared to open radical nephrectomy (ORN), LRN had a longer operative time (OT) (WMD=15.99, 95% CI: 6.74 to 25.24, p = 0.0007), lower estimated blood loss (EBL) (WMD = -237.07, 95% CI: -300.02 to -174.12, p < 0.00001), lower transfusion rates (OR = 0.37, 95% CI: 0.24 to 0.55, p < 0.00001), and shorter length of stay (LOS) (WMD = -2.95, 95% CI: -3.86 to -2.03, p < 0.00001). No statistically relevant differences were found in overall survival (OS) (HR = 1.04, 95% CI: 0.81 to 1.35, p = 0.76), cancer-specific survival (CSS) (HR = 1.28, 95% CI: 0.97 to 1.68, p = 0.08), progression-free survival (PFS) (HR = 1.20, 95% CI 0.97 to 1.48, p = 0.1), recurrence-free survival (RFS) (OR = 1.27, 95% CI: 0.89 to 1.81, p = 0.56), local recurrence rate (OR = 0.85, 95% CI: 0.42 to 1.71, p = 0.65), and intraoperative and postoperative complications.
For patients with renal tumors (> 7 cm), LRN has specific perioperative advantages over ORN (LOS, EBL, and transfusion rates). However, the OT was prolonged in the LRN group. In addition, no differences in complication or oncological outcomes (OS, CSS, PFS, RFS, and local recurrence rate) were reported.
PROSPERO CRD42022367114.
系统评价腹腔镜根治性肾切除术(LRN)治疗肾肿瘤(>7cm)的有效性和安全性。
系统检索PubMed、Scopus、SinoMed、ScienceDirect 和 Google Scholar 数据库,检索时间截至 2022 年 11 月。采用加权均数差(WMD)、比值比(OR)和风险比(HR)评估汇总结果。
本荟萃分析(18 项研究)显示,与开放根治性肾切除术(ORN)相比,LRN 的手术时间(OT)更长(WMD=15.99,95%CI:6.74 至 25.24,p=0.0007),估计失血量(EBL)更少(WMD=-237.07,95%CI:-300.02 至-174.12,p<0.00001),输血率更低(OR=0.37,95%CI:0.24 至 0.55,p<0.00001),住院时间(LOS)更短(WMD=-2.95,95%CI:-3.86 至-2.03,p<0.00001)。两组的总生存(OS)(HR=1.04,95%CI:0.81 至 1.35,p=0.76)、癌症特异性生存(CSS)(HR=1.28,95%CI:0.97 至 1.68,p=0.08)、无进展生存(PFS)(HR=1.20,95%CI 0.97 至 1.48,p=0.1)、无复发生存(RFS)(OR=1.27,95%CI:0.89 至 1.81,p=0.56)、局部复发率(OR=0.85,95%CI:0.42 至 1.71,p=0.65)和术中术后并发症发生率无统计学差异。
对于肾肿瘤(>7cm)患者,LRN 与 ORN 相比具有特定的围手术期优势(LOS、EBL 和输血率)。然而,LRN 组的手术时间延长。此外,在并发症或肿瘤学结局(OS、CSS、PFS、RFS 和局部复发率)方面未报告差异。
PROSPERO CRD42022367114。